Christopher Brooke
Chief Operating Officer at SwanBio Therapeutics, Inc.
Net worth: 165 734 $ as of 2024-04-29
Profile
Christopher Brooke is the founder of Rumpus Therapeutics.
He is currently the Chief Operating Officer at SwanBio Therapeutics, Inc. where he started in 2023.
Prior to this, he was the Chief Operating Officer at Aytu Biopharma, Inc. from 2021 to 2023.
Mr. Brooke received his undergraduate degree from Colgate University and his MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AYTU BIOPHARMA, INC.
1.05% | 2023-08-10 | 58,357 ( 1.05% ) | 165 734 $ | 2024-04-29 |
Christopher Brooke active positions
| Companies | Position | Start |
|---|---|---|
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Chief Operating Officer | 2023-10-15 |
Former positions of Christopher Brooke
| Companies | Position | End |
|---|---|---|
| AYTU BIOPHARMA, INC. | Chief Operating Officer | 2023-10-12 |
| Rumpus Therapeutics | Founder | - |
Training of Christopher Brooke
| Colgate University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Rumpus Therapeutics | |
| Aytu Biopharma, Inc. |
- Stock Market
- Insiders
- Christopher Brooke
